Stay updated with breaking news from David Bartel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) had its target price boosted by research analysts at HC Wainwright from $350.00 to $400.00 in a report issued on Tuesday, The Fly reports. HC Wainwright’s target price suggests a potential upside of 154.08% from the stock’s current price. Several other equities analysts also recently weighed in on ALNY. […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) has been assigned a consensus rating of “Buy” from the eighteen research firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12-month target price among […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2022 earnings per share estimates for Alnylam Pharmaceuticals in a report issued on Monday, April 4th. Oppenheimer analyst L. Gershell now forecasts that the biopharmaceutical company will earn ($1.76) per share for the quarter, down from their previous estimate of […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) Director Steven M. Paul sold 15,000 shares of the stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $170.69, for a total transaction of $2,560,350.00. The sale was disclosed in a filing with the SEC, which is available through this […]